secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-141371
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q1 2023: R&D spend $12.4M; CABA-201 IND cleared, Fast Track granted
--------------------------------------------------------------------------------

- R&D expenses $12.4M (Q1 2023) vs $9.2M (Q1 2022); G&A $4.5M vs $3.8M.
- Cash and equivalents $93.8M as of March 31, 2023; runway into Q1 2025.
- FDA cleared IND for CABA-201 Phase 1/2 trial in lupus nephritis and SLE; Fast Track Designation granted.
- Trial to enroll 6 LN and 6 SLE patients at 1.0x10^6 cells/kg; three-month efficacy data expected H1 2024.
- Preclinical and updated DSG3-CAART data to be presented at ASGCT 26th Annual Meeting May 16-20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/0001193125-23-141371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523141371/d669630d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-141371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer